In his keynote address, Prof. Sastry emphasized that AI is dramatically accelerating drug discovery timelines, reducing costs, and enabling precision-driven research outcomes.

TechForce Robotics contributes to this evolution by embedding AI-driven SOP intelligence and real-time monitoring into its robotic systems. This enables compliance to function as an integrated, ...

As high school prom season nears, and with summer vacation just around the corner, more teens will be on the roads.  With ...

An officer observed a bicyclist riding the wrong way in a directional bike lane, and the bicycle did not have a functioning front light. A traffic stop was conducted, and the bicyclist consented to ...

Drug resistance remains a central barrier to durable responses across cancer therapies, spanning targeted agents, cytotoxic chemotherapy, endocrine ...

Cabana Golf introduces outdoor golf simulators, bringing realistic, space-free golf experiences to backyards, patios, ...

PumasAI, a science-first organization that turns data into life-saving decisions faster, today announced a major presence at ...

DNA robots are emerging as tiny programmable machines that could one day deliver drugs, hunt viruses, and build ...

BOCA RATON, FL AND TORONTO, ONTARIO, March 16, 2026 (GLOBE NEWSWIRE) -- GNQ Insilico Inc. (“GNQ” or the “Company”), a corporation formed under the federal laws of Canada, and IB Acquisition Corp.

Abstract: Deep learning-based methods for drug target binding affinity (DTA) prediction are improving the efficien cy of drug screening, but some limitations persist in current methodologies. Notably, ...